|
Total Participants
|
24
|
|
Total 2nd response
|
18
|
|
Total study completion rate
|
68%
|
|
Percent of patient with epistaxis pre-treatment
|
79%
|
|
Average number of epistaxis events per month per patient pre-treatment
|
17
|
|
Average number of epistaxis events per month per patient post-treatment
|
4
|
|
Percent of patients with complete resolution epistaxis
|
61%
|
|
Percent of patients with partial resolution epistaxis
|
28%
|
|
Percent of patients with no decrease in epistaxis
|
11%
|
|
Percent of patients with decreased severity of epistaxis
|
94%
|
|
Percent of patients with decreased duration of epistaxis episodes
|
82%
|
|
Percent of patients tolerating treatment with NoBleed
|
94%
|
| Percent of patients who would recommend this product |
88% |
NoBleed Preliminary Efficacy Study
